Summary:
In patients with type 2 diabetes undergoing laparoscopic colorectal cancer radical resection, intraoperative dexmedetomidine at a loading dose of 1 μg/kg and maintenance dose of 0.25 μg/kg/h significantly maintained better perioperative blood glucose stability compared to control and higher-dose dexmedetomidine groups (0.5 μg/kg/h and 0.75 μg/kg/h), though it was associated with minimal adverse effects and no delay in extubation.
| PICO | Description |
|---|---|
| Population | Adult patients with type 2 diabetes mellitus (T2DM) undergoing laparoscopic colorectal cancer radical resection. |
| Intervention | Dexmedetomidine, loading dose 1 μg/kg followed by maintenance infusion of 0.25 μg/kg/h (Group D1). |
| Comparison | Control group receiving no dexmedetomidine (Group C), and higher-dose dexmedetomidine groups: 0.5 μg/kg/h (Group D2) and 0.75 μg/kg/h (Group D3) after same 1 μg/kg loading dose. |
| Outcome | Group D1 showed less fluctuation in perioperative blood glucose levels without significant hyperglycemia or delay in extubation. Groups D2 and D3 presented significantly higher glucose levels at several intraoperative timepoints and greater variability compared to the control. |
Source: Wei Dai, et al. “Effect of dexmedetomidine on perioperative blood glucose regulation in type 2 diabetic patients undergoing laparoscopic colorectal cancer radical resection: a randomised double-blinded controlled trial.” Read article here.
